Again and again, I accidentally come across some compound that seems to have profound effects for PD, and yet there is no one getting paid to tell us about it, so we never hear about unless it is through each other.
For example, here's a phase 2 trial completed 4 YEARS AGO for a compound shown in the 1980's to help PD and it shows patients having a REVERSAL of symptoms for as long as they got the 2/day injections. The patients were forced to stop taking it and began showing normal progression of PD in the 2 years since. It seems to be very expensive as it needs to be derived from animals, but it might be much cheaper if there was a larger need for it.
The trial was proposed 13 YEARS AGO. The problem is that it is a natural compound, so no one can make a profit from it.
(subcutaneous injection, 100 mg, 2 doses per day)
The link below is the first of 5 research papers in the 1980's showing its benefit for PD in animals. There are literally 100 natural compounds that have shown the same results in animals, although many of them will probably not reach the human brain, including the most powerful.
Three years ago GM1 was discussed on this web site:
And an interesting comment from one poster (3 years ago)
"In the last five years I have seen dozens of these studies. I never see where they actually go into treatment. I am receiving the same treatment I would have gotten twenty years ago. Seems odd."
Moreover, this natural compound may be the underlying reason nilotinib works. The tyrosine kinase inhibitors like nilotinib induce GM1 (see 2006 article jimmunol.org/content/176/2/... ). So it begs the question: exactly why are the researchers interested in leukemia's tyrosine kinase inhibitors in the first place? Did they or Novartis see the work on GM1 and say, hmmm, is there a pharmaceutical that can do this?
There are 61 papers with GM1 Ganglioside and Parkinson's in the abstract. Here's one of them:
"The nigral neurons of PD subjects that were severely deficient in GM1 showed subnormal levels of tyrosine phosphorylated RET. Also in PD brain, GM1 levels in the occipital cortex, a region of limited PD pathology, were significantly below age-matched controls, suggesting the possibility of systemic GM1 deficiency as a risk factor in PD. This would accord with our finding that mice with partial GM1 deficiency represent a faithful recapitulation of the human disease. Together with the previously demonstrated age-related decline of GM1 in human brain, this points to gradual development of subthreshold levels of GM1 in the brain of PD subjects below that required for effective GDNF signaling. This hypothesis offers a dramatically different explanation for the etiology of sporadic PD as a manifestation of acquired resistance to GDNF. "
In the past 5 years, I'm seeing more work on natural compounds than in the past 25 years, and I can order the strangest of these direct from china, either not available here or much more expensive (100x more expensive in new or strange ones).
I wonder if PD has been cured and we are not told because the government wants us to spend $5,000 to $100,000 per year on pharmaceuticals.